{"id":65052,"date":"2026-05-12T15:00:35","date_gmt":"2026-05-12T07:00:35","guid":{"rendered":"https:\/\/flcube.com\/?p=65052"},"modified":"2026-05-12T15:00:36","modified_gmt":"2026-05-12T07:00:36","slug":"yifan-pharmaceutical-licenses-ryzneuta-to-french-distributor-intsel-chimos-for-exclusive-commercialization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65052","title":{"rendered":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization"},"content":{"rendered":"\n<p><strong>Yifan Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002019:SHE\">SHE: 002019<\/a>) announced a licensing agreement with <strong>Intsel Chimos SAS<\/strong>, the French pharmaceutical distributor, granting <strong>exclusive commercialization rights<\/strong> for <strong>Ryzneuta (efbemalenograstim alfa, F-627)<\/strong> in <strong>France<\/strong>. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan&#8217;s proprietary <strong>Di-Kine bimolecular technology platform<\/strong> and is indicated for the prevention and treatment of <strong>chemotherapy-induced neutropenia<\/strong> in cancer patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-framework\">Transaction Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Yifan Pharmaceutical Co., Ltd. (SHE: 002019)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Intsel Chimos SAS (France)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Ryzneuta (efbemalenograstim alfa, F-627) \u2013 rhG-CSF<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Exclusive rights for France<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Proprietary Di-Kine bimolecular technology<\/td><\/tr><tr><td><strong>Previous Partnerships<\/strong><\/td><td>Vitalis Therapeutics Pty Ltd for Australia and New Zealand<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-innovation\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Recombinant human G-CSF (rhG-CSF) with enhanced properties<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Di-Kine bimolecular technology enabling long-lasting and potent biological characteristics<\/li>\n\n\n\n<li><strong>Therapeutic Indication:<\/strong> Prevention and treatment of chemotherapy-induced neutropenia in cancer patients<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Leukopoietic agent stimulating neutrophil production and function<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Extended half-life potentially enabling less frequent dosing compared to standard G-CSF products<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Biosimilar\/biobetter positioning in established $5+ billion global G-CSF market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>European Market Entry<\/strong><\/td><td>France represents gateway to broader European G-CSF market with established reimbursement pathways<\/td><\/tr><tr><td><strong>Distribution Partnership<\/strong><\/td><td>Leverages Intsel Chimos&#8217; established hospital and oncology distribution network in France<\/td><\/tr><tr><td><strong>Global Expansion Strategy<\/strong><\/td><td>Part of systematic international rollout following Australian\/New Zealand partnership<\/td><\/tr><tr><td><strong>Technology Validation<\/strong><\/td><td>International partnerships validate Yifan&#8217;s proprietary Di-Kine platform capabilities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The agreement demonstrates Yifan&#8217;s successful strategy of partnering with regional specialists to access high-value markets while retaining manufacturing and technology control.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>French G-CSF Market:<\/strong> Estimated \u20ac150\u2013200 million annual market with strong demand from oncology centers<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> | Established players include Amgen&#8217;s Neupogen\/Neulasta and multiple biosimilars; differentiation through dosing convenience critical<\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong> | Likely approved via centralized EMA procedure or national French authorization based on existing approvals<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> | Estimated peak annual revenue of \u20ac20\u201330 million from French market opportunity<\/li>\n\n\n\n<li><strong>Strategic Implications<\/strong> | Success in France may catalyze additional European partnerships and expand Yifan&#8217;s global footprint<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding licensing agreements, regulatory pathways, market opportunities, and commercial expectations for Ryzneuta. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market access challenges, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1281,563],"class_list":["post-65052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-she-002019","tag-yifan-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan&#039;s proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65052\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization\" \/>\n<meta property=\"og:description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan&#039;s proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65052\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-12T07:00:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-12T07:00:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization\",\"datePublished\":\"2026-05-12T07:00:35+00:00\",\"dateModified\":\"2026-05-12T07:00:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1204.webp\",\"keywords\":[\"SHE: 002019\",\"Yifan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65052#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65052\",\"name\":\"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1204.webp\",\"datePublished\":\"2026-05-12T07:00:35+00:00\",\"dateModified\":\"2026-05-12T07:00:36+00:00\",\"description\":\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan's proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65052\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1204.webp\",\"width\":1080,\"height\":608,\"caption\":\"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65052#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization - Insight, China&#039;s Pharmaceutical Industry","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan's proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65052","og_locale":"en_US","og_type":"article","og_title":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization","og_description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan's proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.","og_url":"https:\/\/flcube.com\/?p=65052","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-12T07:00:35+00:00","article_modified_time":"2026-05-12T07:00:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65052#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65052"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization","datePublished":"2026-05-12T07:00:35+00:00","dateModified":"2026-05-12T07:00:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65052"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65052#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","keywords":["SHE: 002019","Yifan Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65052#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65052","url":"https:\/\/flcube.com\/?p=65052","name":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65052#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65052#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","datePublished":"2026-05-12T07:00:35+00:00","dateModified":"2026-05-12T07:00:36+00:00","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced a licensing agreement with Intsel Chimos SAS, the French pharmaceutical distributor, granting exclusive commercialization rights for Ryzneuta (efbemalenograstim alfa, F-627) in France. The long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) leverages Yifan's proprietary Di-Kine bimolecular technology platform and is indicated for the prevention and treatment of chemotherapy-induced neutropenia in cancer patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65052#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65052"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65052#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","width":1080,"height":608,"caption":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65052#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yifan Pharmaceutical Licenses Ryzneuta to French Distributor Intsel Chimos for Exclusive Commercialization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65052"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65052\/revisions"}],"predecessor-version":[{"id":65055,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65052\/revisions\/65055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65054"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}